Carpal Tunnel Syndrome ; etiology ; Humans ; Occupational Diseases ; etiology

Adult ; Carcinoma, Neuroendocrine ; Carcinoma, Small Cell ; Ear Neoplasms ; Ear, Middle ; pathology ; Female ; Humans

Objective To study the expression and significance of ?-catenin in keratosic dermatosis and non-melanocytic skin tumors. Methods ?-catenin expression was determined in 10 specimens of normal skin,10 cases of seborrheic keratosis(SK),26 cases of actinic keratosis(AK),17 cases of Bowen's disease(BD) and 35 cases of primary cutaneous squamous cell carcinoma(SCC) by immunohistochemical EnVision two-step staining method. Results The expression of ?-catenin was significantly higher in SK,AK,BD and SCC than in normal skin(P0.05),but that was significantly lower in SK and AK than in BD(P0.05). Conclusion The cytoplasmic and/or nuclear expression of ?-catenin may play a role in the progression from normal skin to keratosic dermatosis and non-melanocytic skin tumors.

This study aimed to construct full-length cDNA clones of the Japanese encephalitis virus (JEV). SA14-14-2 strain and discuss the feasibility of constructing chimeric viruses for exogenous gene expression based on the JEV genetic skeleton. Long-fragment RT-PCR techniques were applied to amplify JEV cD-NAs, and two amplified fragments with corresponding restriction endonuclease sites at both ends were cloned into the pACYC184 vector sequentially. Using standard molecular techniques, the enhanced green fluorescent protein (EGFP) gene was inserted into the 3' non-coding region of JEV as a reporter gene. After in vitro transcription and transfection procedures, wild-type JEV and chimeric JEV that expressed the EGFP as the reporter gene were successfully rescued. The recovered viruses were characterized by RT-PCR, plaque assays, and direct fluorescence microscopy. After six serial passage generations, the stability of the recovered viruses were studied in terms of virus growth characteristics and structural gene expression. The results showed that cDNA clones of rJEV and rJEV-EGFP were successfully constructed and rescued in BHK-21 cells after in vitro transcription and transfection. Each generation of the recovered viruses was stable and the chimeric virus rJEV-EGFP could stably express EGFP. The findings of this study indicate that both rJEV and rJEV-EGFP could be constructed and rescued in BHK-21 cells, and the JEV SA14-14-2 strain could be obtained as a viral vector to express foreign genes.
Cloning, Molecular ; DNA, Complementary ; genetics ; metabolism ; Encephalitis Virus, Japanese ; genetics ; metabolism ; Encephalitis, Japanese ; virology ; Gene Expression ; Genetic Vectors ; genetics ; metabolism ; Green Fluorescent Proteins ; genetics ; metabolism ; Humans ; Vaccines, Attenuated ; genetics ; metabolism ; Viral Vaccines ; genetics ; metabolism

Child ; Chorea ; physiopathology ; Dyskinesias ; diagnosis ; physiopathology ; Humans ; Polysomnography ; methods ; Sleep ; physiology

Adult ; Antibiotics, Antineoplastic ; therapeutic use ; Benzamides ; Blast Crisis ; drug therapy ; Drug Resistance, Neoplasm ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; drug therapy ; Male ; Piperazines ; pharmacology ; Pyrimidines ; pharmacology ; Sirolimus ; therapeutic use

Objective: To evaluate the clinical efficacy and tolerability of a 3-week regimen of low dosage of paclitaxel (PTX) combined with gemcitabine (GEM) for metastatic breast cancer (MBC) patients who had been pretreated with antracyclines. Methods: Thirty two MBC patients who received antracyclines chemotherapy were recruited in this study. They were infused with PTX (120 mg/m2) for 3 h on d 1, followed by 30-min intravenous infusion with GEM 900 mg/m2) on d 1 and d 8. The combined chemotherapy was repeated every 21 d as one cycle. Maximum 6 cycles were given. Toxicity was evaluated on all the patients. The clinical efficacy was evaluated on those who had received at least 2 cycles of combined chemotherapy. Results: All of the 32 patients completed 156 cycles of chemotherapy with a median number of five cycles per patient. Four patients (12.5% %) achieved a complete response, 15 patients (46.9%) had a partial response, with an overall objective response rate of 59.4% (95% CI: 42.4%-76.4%). Stable disease was documented in 8 patients (25%) while progressive disease occurred in 5 patients (15.6%). There were no differences in response rates between the ER(+) and ER(-) patients, between the patients aged ≥50 years and <50 years, and between the patients with invasive ductal cancer and invasive lobular cancer (P = 0.783, P = 0.328, P = 0.794,respectively). The average follow-up period was 20.2 months, the median time to progression was 10.0 months, and median overall survival time was 20.0 months. Nine patients were alive with no progression at the end of follow-up. Conclusion: The 3-week combined chemotherapy of low dosage of PTX with GEM is effective for breast cancer patients who had been treated with antracyclines. The hematologic and non-hematologic toxicities are well-tolerated.

Abnormalities, Multiple ; physiopathology ; Bronchoscopy ; Diagnosis, Differential ; Hirschsprung Disease ; diagnosis ; physiopathology ; Humans ; Hypoventilation ; complications ; physiopathology ; Infant ; Laryngoscopy ; Male ; Respiratory Insufficiency ; complications ; diagnosis ; physiopathology ; Sleep Apnea, Central ; etiology ; Syndrome

Antigens, CD20 ; metabolism ; CD79 Antigens ; metabolism ; Carcinoma, Neuroendocrine ; metabolism ; pathology ; Carcinoma, Renal Cell ; metabolism ; pathology ; Diagnosis, Differential ; Female ; Follow-Up Studies ; Humans ; Kidney Neoplasms ; metabolism ; pathology ; Leukocyte Common Antigens ; metabolism ; Lymphoma, Large B-Cell, Diffuse ; metabolism ; pathology ; Middle Aged ; Neoplasms, Multiple Primary ; metabolism ; pathology ; Nephrectomy ; PAX5 Transcription Factor ; metabolism ; Wilms Tumor ; metabolism ; pathology

Child ; Codon, Nonsense ; genetics ; DNA Mutational Analysis ; DNA Primers ; genetics ; Dent Disease ; diagnosis ; genetics ; Exons ; genetics ; Humans ; Infant ; Male ; Mutation ; Oculocerebrorenal Syndrome ; diagnosis ; genetics ; Phosphoric Monoester Hydrolases ; genetics ; Polymerase Chain Reaction